203. Use of New Antibiotics – FDA Indications and Beyond
Saturday, October 29, 2016: 8:30 AM-10:00 AM
Room: Theater C

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss recently approved antibiotics for FDA indicated infections
  • recognize unique features of recently approved antibiotics
  • identify patient scenarios for which the new agents maybe optimal for non-FDA approved indications

Target Audience: Academicians, Clinicians, Fellows, Infectious diseases pediatricians, Infectious diseases physicians, Members-in-training, Pharmacists

Tracks: Pediatric ID, Adult ID

Moderators:  David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health and Deborah Goff, PharmD, Ohio State University

8:30 AM
Gram-Positive Antibacterials
Helen W. Boucher, MD, FIDSA

8:55 AM
9:00 AM
9:25 AM
9:30 AM
Barbara D. Alexander, MD, MHS, FIDSA

9:55 AM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-280-L01-P


D. R. Andes, Astellas, Roche, Melinta, Actelion, Theravance, Paratek, Zavante, Scynexis: Grant Investigator , Grant recipient
Actelion, Melinta, Scynexis, Roche, Theravance, Meiji: Consultant , Consulting fee

D. Goff, Allergan: Scientific Advisor , Consulting fee
Cepheid: Scientific Advisor , Consulting fee
Merck: Speaker's Bureau , Speaker honorarium
Astellas: Speaker's Bureau , Speaker honorarium
Medicine Company: Scientific Advisor , Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.